Natural History of Intracranial Atherosclerotic Disease by Yuehua Pu et al.
REVIEW ARTICLE
published: 10 July 2014
doi: 10.3389/fneur.2014.00125
Natural history of intracranial atherosclerotic disease
Yuehua Pu, Xin Dou and Liping Liu*
Department of Neurology, Beijing Tiantan Hospital of Capital Medical University, Beijing, China
Edited by:
Firas Al-Ali, Akron General Medical
Center, USA
Reviewed by:
Ashish Nanda, University of Missouri,
USA
Firas Al-Ali, Akron General Medical
Center, USA
*Correspondence:
Liping Liu, Department of Neurology,
Beijing Tiantan Hospital of Capital
Medical University, Tiantan Xili 6,
Beijing 100050, China
e-mail: lipingsister@gmail.com
Intracranial atherosclerotic disease was very common among stroke patients of Asians,
Blacks, and Hispanics ancestry. Furthermore, stroke patients with intracranial athero-
sclerosis (ICAS) have higher recurrence rate of cerebral ischemia and death than those
without ICAS. However, the natural history of intracranial atherosclerotic disease is still
in controversy. Most of the studies were retrospective and randomized controlled trial of
drugs. This review summarized the prognosis of symptomatic and asymptomatic intracra-
nial atherosclerotic disease in order to guide clinical decision-making and further clinical
research.
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INTRODUCTION
The natural history of disease refers to a description of the uninter-
rupted progression of a disease in an individual from the moment
of exposure to causal agents until recovery or death. Knowledge of
the natural history of disease ranks alongside causal understand-
ing in importance for disease prevention and control. It includes
four stages: biologic onset, subclinical stage, clinical stage, and out-
come. In this review, natural history refers to the clinical outcome
under current treatment (including death, recurrent cerebrovas-
cular, or other vascular events, etc.) and regression of intracranial
atherosclerotic lesions.
Many studies had confirmed that extracranial carotid ather-
osclerotic stenosis was the most common vascular lesion found
in stroke patients in Caucasians, otherwise intracranial athero-
sclerotic disease was found commonly among stroke patients of
Asians, Blacks, and Hispanics ancestry (1–3). Stroke patients with
intracranial atherosclerosis (ICAS) have higher recurrence rate of
cerebral infarct event and death. Owing to heterogeneity in vascu-
lar anatomy and physiology, atherosclerosis in different vessels may
represent diseases with fundamentally distinct courses. Therefore,
it is important to distinguish vascular territories when studying
the natural history of this condition (4).
PROGRESSION OF CEREBRAL ATHEROSCLEROTIC LESIONS
Atherosclerosis is a progressive disease that starts early in life and is
manifested clinically as coronary heart disease (CHD), cerebrovas-
cular disorders, or peripheral arterial disease (5). This disease can
be hidden in the human body for many years and ultimately lead to
vascular remodeling. Glagov and co-workers (6) put forward the
concept of vascular remodeling early in the 80s of the last century.
They held that it leads to expansion of the vascular wall at first
and does not influence diameter of lumen and supply of blood
in the early atherosclerosis, and then to late, it leads to stenosis
of blood vessel diameter, thus it causes changes in hemodynamics
and even occlusion. Early in 1994, Schwarze et al. (7) had found
that intracranial arterial stenoses are dynamic lesions, and that
they can evolve and cause further reductions of the arterial diame-
ters after relatively short periods of time. They observed a group of
patients with a mean follow-up of 21 months. Ten (35%) arteries
with lesions had TCD evidence of progression.
Wong and his colleagues (8) observed 143 patients with symp-
tomatic middle cerebral artery (MCA) stenosis or occlusion. They
repeated TCD examinations 6 months after the initial examina-
tions and recorded any stroke or coronary events during this
period. The changes of MCA flow velocities were categorized
as normalized artery, stable artery, and progressed artery, which
were determined according to the changes of MCA velocities at
6 months. By analyzing both the initial and repeated TCD find-
ings, there were 42 patients (29%) in the normalized group, 88
patients (62%) in the stable group, and 13 patients (9%) in the
progressed group. For the clinical events during the 6-month
period, 18(12.6%) of the patients had further documented vas-
cular events, including 10 recurrent strokes (9 ischemic strokes
and 1 hemorrhagic stroke), 5 TIAs, and 3 acute coronary syn-
dromes. Progression of MCA occlusive diseases is associated with
an increased risk of vascular events. Jeon et al. (9) studied 103
patients with MCA stenosis (include symptomatic and asympto-
matic). To understand its progress situation, patients need to take
the TCD reexamination at 6 months after the initial examination.
After 6 months, 13 (12.6%) patients showed worsening, whereas
90 were stationary or showed regression upon TCD examination.
In this study, the definition of the progression of MCA stenosis as
determined TCD examination was not the same as Wong’s.
So, intracranial artery stenosis is a process of dynamic changes.
The speed of progress is different from each other. Through the
prospective study, it is found that lesions may progress, improve,
or no change over a period of time. The proportion of progression
is about 9–12% for 6 months. The possibility of the progression
depends on the time, and it may be greater as time goes on. The
progression of stenosis may lead to increased risk of vascular
events. However, there is a lack of large sample studies in this
area, and the risk factors leading to advances in intracranial artery
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stenosis still remain to be determined. Most of the present studies
are based on TCD. This examination method needs to a higher
requirement for operators and exists to some limitations. In the
future, it is urgent to develop the studies based on MRA, CTA,
or DSA.
THE CLINICAL OUTCOME OF INTRACRANIAL ARTERY
STENOSIS
Major trials investigating prognosis of asymptomatic and symp-
tomatic intracranial large artery stenosis or occlusion disease was
shown in Table 1.
ASYMPTOMATIC INTRACRANIAL ARTERY STENOSIS
Kremer and co-workers (16) follow-up 50 white patients with
asymptomatic atherosclerotic middle cerebral artery stenosis
(MCAS) as determined TCD examination for [mean (SD)]
815(351) days. The results showed that no patient suffered an
ischemic event in the MCAS territory; one had a transient ischemic
attack (TIA) in the contralateral hemisphere; three patients died
(one from a subdural hematoma in the contralateral hemisphere,
and two from non-stroke-related causes) during the follow-up
period. So they came to the conclusions that asymptomatic MCAS
of atherosclerotic origin appears to have a benign long-term prog-
nosis with a low risk of ipsilateral stroke in medically treated white
patients. Kern et al. (10) took the comparison of the symptomatic
and asymptomatic MCA stenosis in patients with recurrent stroke
risk and came to a similar conclusion. The authors observed 102
consecutive patients with significant MCA stenosis or occlusion
as demonstrated by transcranial Doppler and transcranial color-
coded duplex ultrasonography. Patients with symptomatic MCA
Table 1 | Major trials investigating prognosis of asymptomatic and symptomatic intracranial large artery stenosis or occlusion disease.
Reference Design No. of
patients
Mean
follow-up
(Month)
Degree of
stenosis (%),
diagnosis method
OutcomeAssessment Prognosis
Kern et al. (10)
(For
asymptomatic
MCA)
Prospective,
observational
102 30.7 TCD and TCCD Cerebrovascular events,
including TIA and stroke
Overall stroke risk was 12.5% per year
(ipsilateral: 9.1%) for patients with
symptomatic MCA disease the annual;
that of asymptomatic MCA disease
was only 2.8% (ipsilateral: 1.4%).
Wong and Li
(11)
Prospective,
observational
705 42 >50%, by TCD Further vascular events
(including TIA, stroke, or
acute coronary
syndrome) or death
Annual risk of death: 11.2%. Annual
risk of cerebrovascular event: 17.1%
(For patients only have intracranial
stenosis or occlusion)
Chimowitz
et al. (12)
Randomized,
double-blinded,
multicenter trial
569 21.6 50~99%, by DSA The primary end point:
ischemic stroke, brain
hemorrhage, or death
from vascular causes
other than stroke
The primary end point occurred in
22.1% of the patients in the aspirin
group and 21.8% of those in the
warfarin group.
Mazighi et al.
(13)
Prospective,
multicenter,
non-randomized
102 23.4 50~99%, by DSA or
ultrasonography and
confirmed by MRA,
angiography, or CT
Cerebrovascular event:
ischemic stroke and TIA,
or vascular death.
The overall vascular death rate was
8.8%. The rate of patients had a
cerebrovascular event was 38.2%.
Chimowitz
et al. (14)
Investigator-
initiated,
randomized,
clinical trial
451 11.9 50~99%, by
angiography
The primary end point:
stroke or death within
30 days or stroke in the
territory of the qualifying
artery beyond 30 days.
1-year rates of the primary end point
was 20.0% in the PTAS group and
12.2% in the medical-management
group.
Miao et al. (15) prospective,
randomized,
controlled,
single-center
70 12 Symptomatic MCA
stenosis ≥70%, by
DSA
The end point events: any
kind of ipsilateral stroke
or transient ischemic
attack, or death from any
origin
30-day rate of end point events was
8.3% for PTAS group and 5.9% for
medical group. One-year rate of end
point events was 19.4 and 17.6%.
TIA, transient ischemic attack; TCD, transcranial Doppler; TCCD, transcranial color-coded duplex ultrasonography; PSV, peak systolic flow velocity; DSA, digital sub-
traction angiography; MCA, middle cerebral artery; PTAS, percutaneous transluminal angioplasty and stenting; MRA, magnetic resonance angiography; CT, computer
tomography; WASID: warfarin–aspirin symptomatic intracranial disease; GESICA: Groupe d’Etude des stenoses intra-craniennes atheromateuses symptomatiques;
SAMMPRIS, stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis.
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disease had an overall stroke risk of 12.5% per year (ipsilateral:
9.1%), whereas the annual incidence in primarily asymptomatic
MCA disease was only 2.8% (ipsilateral: 1.4%; p< 0.01). It was
significantly lower than that of symptomatic MCA stenosis. Symp-
tomatic MCA disease was an independent predictor for overall
[hazard ratio (HR)] 7.91, 95% CI 2.03–30.79;p< 0.01) and ipsilat-
eral (HR 9.66, 95% CI 1.5–62.25; p= 0.02) cerebrovascular events.
Borozan et al. (17) made a retrospective study for patients with
intracranial ICA stenosis with mean follow-up of 25.5 months, 93
patients were included, and 24% were symptomatic. Patients were
considered for inclusion in this study if a carotid siphon stenosis
of 20% or greater was documented arteriographically, and they
were identified from a review of 885 consecutive cerebral arteri-
ograms. In this study, overall annual rate of stroke per year was
5.1%, annual incidence of ipsilateral stroke was 5.0%, and over-
all mortality was 10.6%. Obviously, subgroup analyses revealed
that for patients with symptomatic stenosis, annual incidence of
ipsilateral stroke per year was 6.4%, whereas that of patients with
asymptomatic stenosis was 3.5%.
SYMPTOMATIC INTRACRANIAL ARTERY STENOSIS
Many studies have confirmed that there is a higher risk of death
and vascular events in patients with ICAS. Wong et al. (11)
included 705 patients with acute ischemic stroke and followed up
for 42 months. The annual recurrent stroke rates during the first
year were 10.9% for patients without vascular lesion, 17.1% for
ICAS only, and 24.3% for both intracranial and extracranial ath-
erosclerosis; for the second year, the rates were 7.5, 8.6, and 7.7%,
respectively. More occurrence of death (log rank, 5.19; p= 0.02) or
cerebrovascular event (log rank, 9.68; p= 0.002) was found among
patients with than those without vascular lesions. Patients with
both intracranial and extracranial arterial lesions were at high-
est risk of death (log rank, 9.64; p= 0.008) and cerebrovascular
event (log rank, 11.56; p= 0.003). They came to the conclusions
that patients with ICAS, especially co-existing extracranial carotid
disease, are at higher risk of suffering death or further vascular
event.
The GESICA study (13) was another prospective, multicenter,
non-randomized study from France. The objective was to evalu-
ate the natural history of ICAS and, in those patients refractory
to medical treatment, the outcomes associated with intracranial
angioplasty. Patients aged 18–80 were enrolled with symptoms
attributed to a single ICAS of greater than or equal to 50%.
Optimal medical therapy of vascular risk factors and preven-
tive antithrombotic therapy were at the discretion of the local
investigator. Intracranial stenosis (50–99%) had to be demon-
strated by either DSA or ultrasonography and confirmed by one
of the following methods: MRA, angiography, or CT. During a
mean follow-up of 23.4 months, 38.2% of the patients had a cere-
brovascular event: ischemic stroke in 13.7%, and TIA in 24.5%.
Cardiovascular events occurred in 18.6% of patients. The overall
vascular death rate was 8.8%. At the same time, the study also held
that clinically significant hemodynamic stenoses were associated
with stroke recurrence and may help identify a high-risk subset of
patients.
Specific medicine was still not found for ICAS patients.
Antithrombotic therapy for intracranial arterial stenosis was
evaluated in the Warfarin versus Aspirin for Symptomatic
Intracranial Disease (WASID) trial (18). They reported the risk
of stroke in the territory of the stenotic artery was highest with
severe stenosis ≥70% (HR 2.03; 95% CI 1.29–3.22; p< 0.0025).
In the NIH registry on use of the Wingspan stent for sympto-
matic 70–99% intracranial arterial stenosis (19), comparison of
the event rates in high-risk patients in WASID do not rule out
either that stenting could be associated with a substantial rela-
tive risk reduction (e.g., 50%) or has no advantage compared with
medical therapy. The frequency of any stroke, intracerebral hemor-
rhage, or death within 30 days or ipsilateral stroke beyond 30 days
was 14.0% at 6 months (95% CI= 8.7–22.1%). The frequency
of ≥50% restenosis on follow-up angiography was 13/52 (25%).
The SAMMPRIS (14) study compared percutaneous translumi-
nal angioplasty and stenting (PTAS) with medical management to
prevent recurrent stroke. One-year rates of the primary end point
(stroke or death within 30 days after enrollment or after a revas-
cularization procedure) were 20.0% in the PTAS group and 12.2%
in the medical-management group.
In the Chinese IntraCranial AtheroSclerosis (CICAS) study
(20), we evaluated 2864 consecutive patients who experienced
an acute cerebral ischemia within 7 days of symptom onset. The
prevalence of ICAS was 46.6% (1,335 patients, including 261
patients with co-existing extracranial carotid stenosis). Patients
with ICAS had more severe stroke at admission and stayed longer
in hospitals than those without intracranial stenosis (median
NIHSS 3 vs. 5; median length of stay 14 vs. 16 days, respectively,
both p< 0.0001). After 12 months, recurrent stroke occurred in
3.34% of patients with no stenosis, 3.82% for 50–69% stenosis,
5.16% for 70–99% stenosis, and 7.40% for total occlusion.
CLINICAL OUTCOMES OF ICAS BY DIFFERENT VESSELS
The clinical outcomes of ICAS may depend on the situation of ves-
sels (21). A multicenter prospective study from German showed
the prognosis of basilar artery occlusion was worse than carotid
artery and MCA occlusion (22). The location of lesions may affect
prognosis and treatment. It is necessary to take a review to natural
history based on distribution of ICAS.
Intracranial internal carotid artery
In 1982, Craig et al. (23) published their first retrospective study
and explored the natural history of intracranial internal carotid
artery (ICA) atherosclerosis. The diagnosis was confirmed by DSA
to demonstrate that stenosis rate>30%. The results suggested that
overall annual incidence of stroke was 11.6%; annual incidence of
ipsilateral stroke events was 7.6%; symptomatic patients is higher
than that in patients with asymptomatic stenosis in annual recur-
rence rate of cerebral ischemia events (45 vs. 36%); but there
was no differences between the two groups in overall mortality
(42 vs. 45%). In the same year, Marzewki et al. (24) published a
similar retrospective case series study on intracranial ICA steno-
sis. The diagnosis was confirmed by angiography that stenosis
rate >50%. Overall annual recurrence rate of stroke per year was
3.9%; incidence of ipsilateral stroke was 3.1%. Bogousslavsky (25)
observed 22 patients with stenosis rate greater than 30% docu-
mented by angiography. During a mean follow-up of 40.4 months,
seven patients died (32%), and among them, six patients died of
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heart disease and one died of stroke. In this study, annual incidence
of ipsilateral stroke per year was 8.1% and the annual mortality
was 9.5%.
Middle cerebral artery
Although most of previous studies were miniature retrospective
studies, recently, more and more countries and regions successively
carried out a number of large-size prospective studies. These stud-
ies reported that average annual mortality and annual incidence of
ipsilateral stroke were 2.7–7.1%. Furthermore, these studies also
suggested that progression of plaque and appearance of Microem-
bolic signals (MES) often foreshowed stroke recurrence. So these
methods were helpful to screen high-risk patients. For studies
on MCA, they also began from a series of small-sample retro-
spective case studies, which was similar to the related studies on
intracranial ICA and vertebrobasilar artery (VB). The first paper
published in 1979. Hinton et al. (26) analyzed 16 consecutive
patients with symptomatic MCA stenosis. Follow-up was from
1 month to 6 years, and finally 2 of the 16 (12.5%) developed
severe stroke events, which were located in the territory of stenotic
MCA, no deaths. Corston et al. (27) reviewed 21 patients with
symptomatic intracranial artery stenosis confirmed by angiogra-
phy, and among them, 90% had M1 segment of MCA lesions.
During the mean follow-up period of 6.5 years, 5 patients (24%)
suffered stroke events (4 of them were fatal stroke), 10 patients
(48%) died due to various reasons. Annual incidence of stroke was
3.7%, overall annual mortality was 7.1%, and annual incidence of
fatal stroke was 2.9%.
The first prospective study about MCA stenosis was from a sub-
group analysis of intracranial and extracranial bypass (28). This
study was about the efficacy of drug therapy and extracranial–
intracranial bypass operation for ICAS. In the group of drug
therapy, 138 patients with symptomatic MCA stenosis or occlusion
were recruited. During the mean follow-up period of 55.8 months,
23% of patients suffered stroke events in the territory of arbi-
trary vessels and overall annual incidence of stroke was 5.0%. This
study did not report location and mortality of stroke. Arenillas
et al. (29) conducted a prospective study in view of sympto-
matic MCA stenosis. They screened from consecutive TIA or
stroke patients and 40 of them entered this study, which con-
firmed by TCD and cerebral angiography as MCA stenosis. During
the mean follow-up period of 26.5 months, eight patients (20%)
occurred cerebral ischemic event in the territory of stenotic MCA
(six TIAs and two stokes), annual incidence of ipsilateral TIA was
6.8%; annual incidence of ipsilateral stroke was 2.3%. Progres-
sion of stenosis was independent predictors of stroke recurrence.
The results of this study suggested that periodic review of tran-
scranial Doppler ultrasound was helpful to screen patients with
high-risk. Gao et al. (30) provided another method to identify
high-risk population for us. This prospective study observed 114
consecutive patients with acute ischemic stroke. These patients
were confirmed by TCD as MCA stenosis. Each patient received
TCD examination for three consecutive days during acute period,
30 min for each time, which detected the existence of MES. During
the mean follow-up period of 13.6 months, 10 patients recurred
stroke in the territory of stenotic MCA and 9 patients died. Annual
recurrence rate of ipsilateral stroke was 7.8%; overall annual mor-
tality was 7.0%. TCD found that MES was independent predictors
of stroke recurrence. This study not only indicated mechanism of
embolization in stroke recurrence, but also showed a new method
to confirm patients at high-risk – MES detection. Recently, Miao
et al. (15) performed a prospective, randomized, controlled, and
single-center clinical trial to compare PTAS with medical treat-
ment for symptomatic MCA stenosis (≥70%). The PTAS group
received stenting or balloon angioplasty, whereas the medical
treatment group received standard medical treatment (aspirin
100 mg plus clopidogrel 75 mg/day), and all the patients were
under strict control of the risk factors. The end point events
were any kind of ipsilateral stroke or TIA, or death from any
origin during 1-year follow-up. The 1-year rate of end point
events was 19.4 vs. 17.6% (p= 0.85) for PTAS and medical group,
respectively.
Vertebrobasilar artery
Researchers in WASID carried on a investigation, which prompted
that in the case of intracranial artery stenosis, the involved ver-
tebral basilar artery was 35–40% (12). There were also many
limitations in studies of outcomes of posterior circulation ath-
erosclerosis. There exist obvious variation in the average annual
stroke recurrence rate in territory of stenosis artery, overall annual
incidence of stroke, overall annual mortality in these studies, and
range of which was 0–8.7%, 3.0–14.3%, and 2.9–42.8%.
The subgroup analysis from warfarin–aspirin symptomatic
intracranial disease (WAISD) (31) study group showed that 22%
of patients had an ischemic stroke (arbitrary territory of artery),
15% of patients suffered stroke in the territory of the stenotic
artery, and 10.3% of patients died (5.9% of them died of stroke).
These results suggested that annual mortality was 6.2%, overall
incidence of stroke was 13.1% and incidence of stroke in the terri-
tory of vertebral basilar artery was 8.7%. According to the location
of specific plaque, they assessed the recurrence rate of stroke. For
patients with vertebral artery stenosis, annual incidence of stroke
in the territory of the stenotic artery was 7.8%, whereas for patients
with basilar artery stenosis, incidence of stroke was 10.7%. For pos-
terior cerebral artery and posterior inferior cerebellar artery, the
incidence of stroke was 6.0%.
Qureshi et al. (32) published a retrospective multicenter study.
A total of 102 patients were included, which accepted the mean
follow-up period of 15 months. Fourteen patients experienced
recurrent stroke (arbitrary territory of artery). Eight patients expe-
rienced stroke in the territory of vertebral basilar artery. Twenty-
one patients died during follow-up, and among them, 16 patients
died of fatal stroke. These results suggested that overall incidence
of stroke was 11%, annual incidence of stroke in the territory
of vertebral basilar artery was 6.3%, and overall annual mor-
tality was 6.3%. Kaplan–Meier analysis revealed that stroke-free
survival of patients was 76% at 12 months and 48% at 5 years.
This suggested that most of patients with symptomatic intracra-
nial VB stenosis, in the 5 years after the initial onset, would suffer
recurrent stroke or death. In this analysis, elderly and lack of
antiplatelet or anticoagulant therapy are independent predictors
of poor prognosis.
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A series of reports from New England Medical Center Poste-
rior Circulation registry made us better understanding the stroke
in posterior Circulation. The overall 30-day mortality was 3.6%.
Embolic mechanism, distal territory location, and basilar artery-
occlusive disease carried the poorest prognosis. The best outcome
was in patients who had multiple arterial occlusive sites; they
had position-sensitive TIAs during months to years (33). For
patients with moderate to severe BA occlusive disease, the mor-
tality rate was 2.3%, and 62 patients (almost 75%) had minor
or no deficits at follow-up (34). For patients with bilateral ICVA
(intracranial vertebral artery) occlusive disease, the short- and
long-term (mean length of follow-up was 31.4 months) outcomes
were usually favorable, but patients with bilateral ICVA and basi-
lar artery-occlusive lesions often have poor outcomes (35). The
patients with distal territory infarcts due to emboli from the ICVA
had the worst outcome (36).
SUMMARY AND EXPECTATION
Overall, intracranial arterial stenoses are dynamic lesions, and that
they can evolve and cause further reductions of the arterial diam-
eters or further vascular events as time goes on. However, it is
still uncertain that how to recognize high-risk population and
what methods can prevent further vascular event efficiently. On
the other hand, the natural history of symptomatic and asympto-
matic disease is different. The annual incidence of ipsilateral stroke
per year for patients with asymptomatic stenosis was much lower
than that of patients with symptomatic stenosis. Asymptomatic
and symptomatic lesions can transform for each other. But, we do
not yet know how this conversion is made. Furthermore, location
of the diseased vessel may affect prognosis and treatment. There
still lack of large sample, prospective, and observational study to
identify the natural history of intracranial large artery disease by
different vessels.
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